The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Open accessPublished version of a preprint
Abstract
Metabolic dysfunction–associated steatohepatitis (MASH) represents a progressive form of steatotic liver disease which increases the risk for fibrosis and advanced liver disease. The accumulation of discrete species of bioactive lipids has been postulated to activate signaling pathways that promote inflammation and fibrosis. However, the key pathogenic lipid species is a matter of debate. We explored candidates using various dietary, molecular, and genetic models. Mice fed a choline-deficient L-amino acid–defined high-fat diet (CDAHFD) developed steatohepatitis and manifested early markers of liver fibrosis associated with increased cholesterol content in liver lipid droplets within 5 d without any changes in total liver cholesterol content. Treating mice with antisense oligonucleotides against Coenzyme A synthase ( Coasy ) or treatment with bempedoic acid or atorvastatin decreased liver lipid droplet cholesterol content and prevented CDAHFD-induced MASH and the fibrotic response. All these salutary effects were abrogated with dietary cholesterol supplementation. Analysis of human liver samples demonstrated that cholesterol in liver lipid droplets was increased in humans with MASH and liver fibrosis and was higher in PNPLA3 I148M (variants rs738409) than in HSD17B13 variants (rs72613567). Together, these data identify cholesterol in liver lipid droplets as a critical mediator of MASH and demonstrate that Coenzyme A synthase knockdown and bempedoic acid are therapeutic approaches to reduce liver lipid droplet cholesterol content and thereby prevent the development of MASH and liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BA treatment also reduced TG and total cholesterol content in liver LDs.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“BA is a prodrug that requires activation by a liver-specific enzyme, very long-chain ACSL1.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“Notably, bempedoic acid (BA) works as an ACLY inhibitor, which is clinically used as a plasma cholesterol-lowering drug.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“BA is a particularly important therapeutic agent, as it simultaneously inhibits cholesterol synthesis and DNL, making it potentially effective for treating MASH while also improving major CV outcomes [146-148].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
In the citing paper
“It effectively lowers LDL-cholesterol and reduces CV risk without muscle-related side effects.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput
Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S., & Ralser, M. (2020) · Nature Methods · doi:10.1038/s41592-019-0638-x · Cited by 3,343
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationvan der Veen, J. N., Kennelly, J. P., Wan, S., Vance, J. E., Vance, D. E., & Jacobs, R. L. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.04.006 · Cited by 1,514
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Self-citationLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847 · cited 1×
“Instead, other lipid species, such as fatty acids, cholesterol, lysophosphatidic acid, lysophosphatidylcholine, and ceramides, have all been implicated in causing hepatic inflammation and fibrosis ( 4 – 7 ).”
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 2×
“The hydroxysteroid 17 - beta dehydrogenase 13 (HSD17B13) splice site variant (rs72613567) decreases the risk of MASH (29).”
Morino, K. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25151 · Cited by 811
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · cited 1×
“Bempedoic acid works as an ATP - citrate lyase inhibitor, which is clinically used as a plasma cholesterol - lowering drug (21).”
Research works printed but not linked: 1
- 10.1038/s41467-024-49224-x · DOI · Paper page
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
Steinberg, G. R., Gautam, J., Lally, J., Fayyazi, R., Grasset, E., Bhattacharya, D., Fidelito, G., Ahmadi, E., Townsend, L. K., Batchuluun, B., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.015 · Cited by 26
Liu, Y., Wang, Y., Zhou, J., Li, H., Liu, C., Zhong, B., Liu, J., Liu, L., Zhang, L., & Sun, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1718799 · Cited by 16
Lipid metabolism and metabolites: emerging roles in systemic physiology and metabolic diseases
Xu, J., Lu, D., & Huang, X. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.01.006 · Cited by 15
Metadata
- Authors
- Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., Yimlamai, D., Perelis, M., Vatner, D. F., Petersen, K. F., Huttasch, M., Knebel, B., Kahl, S., Roden, M., Samuel, V. T., Tanaka, T., & Shulman, G. I.
- Affiliations
- Chiba University (JP)
- Yale University (US)
- Kazusa DNA Research Institute (JP)
- Ionis Pharmaceuticals (United States) (US)
- Deutsches Diabetes-Zentrum e.V. (DE)
- Düsseldorf University Hospital (DE)
- Veterans Health Administration (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Shulman, Gerald I.
- ORCID
- Sakuma, Ikki
- Gaspar, Rafael C.
- Nasiri, Ali R.
- Dufour, Sylvie
- Kahn, Mario
- LaMoia, Traci E.
- Guerra, Mateus T.
- Taki, Yuki
- Kawashima, Yusuke
- Yimlamai, Dean
- Perelis, Mark
- Vatner, Daniel F.
- Petersen, Kitt Falk
- Huttasch, Maximilian
- Knebel, Birgit
- Kahl, Sabine
- Roden, Michael
- Samuel, Varman T.
- Tanaka, Tomoaki
- Shulman, Gerald I.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2025-05
- Volume
- 122
- Issue
- 18
- Pages
- e2502978122-e2502978122
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC12067271
- OpenAlex
- W4409995331
- Cited by
- 46
- References
- 80
- Citations by year
- 2026: 35 · 2025: 11
- FWCI
- 31.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-10-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion)
- Funders
- Manpei Suzuki Diabetes Foundation (N/A)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F31DK126362, P30 DK34989, R01 DK119968, R01 DK113984, P30 DK045735, R01 DK133143)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- nonalcoholic steatohepatitis, cholesterol, liver fibrosis, choline-deficient L-amino acid-defined diet, bempedoic acid, atorvastatin, antisense oligonucleotides, PNPLA3, HSD17B13, bioactive lipids, liver inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. https://app.cochat.ai/papers/10.1073/pnas.2502978122
- The paper
- Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., Yimlamai, D., Perelis, M., Vatner, D. F., Petersen, K. F., Huttasch, M., Knebel, B., Kahl, S., Roden, M., Samuel, V. T., . . . Shulman, G. I. (2025). Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2502978122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.